Former pharmaceutical executive pleads guilty to insider trading of stock that netted $260,000
A Cambridge-based former executive for Ipsen Bioscience Inc. admitted using insider information to earn $260,000 on the stock market when his company purchased cancer drug company Epizyme, Inc. in 2022, according to federal records. Dishant Gupta was …